Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cx43-M1
- Development stage
- Unknown
- Lead developer
- AlaMab Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraarticular, Intravenous, Intraperitoneal
01
Overview
Cx43-M1 (also known as Cx43(M1) or MHC1) is a first-in-class monoclonal antibody that selectively blocks connexin 43 (Cx43) hemichannels without disrupting gap junction communication. Developed by the laboratory of Dr. Jean X. Jiang at the University of Texas Health Science Center at San Antonio (UT Health San Antonio), the antibody targets the second extracellular loop of Cx43. By inhibiting the pathological opening of Cx43 hemichannels, Cx43-M1 prevents the release of pro-inflammatory and neurotoxic molecules such as ATP and glutamate. The antibody has demonstrated therapeutic potential in preclinical models of osteoarthritis (OA), acute spinal cord injury (SCI), optic nerve injury, and bone loss. AlaMab Therapeutics licensed the technology to develop a humanized version, ALMB-0166, which is currently in clinical development for acute spinal cord injury.
- Other names
- Cx43(M1)mouse-human chimeric MHC1 antibody
02
Targets
GJA1 (Connexin43 Hemichannel)
Beyond the preview
Go deeper on Cx43-M1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cx43-M1.